In vitro activities of colistin combined with imipenem, tigecycline or cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii blood-stream isolates

O. Ak, Demet Hacıseyitoğlu, Y. Çağ, S. Gencer, F. Biteker, S. Özer
{"title":"In vitro activities of colistin combined with imipenem, tigecycline or cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii blood-stream isolates","authors":"O. Ak, Demet Hacıseyitoğlu, Y. Çağ, S. Gencer, F. Biteker, S. Özer","doi":"10.5455/DMM.20160830024755","DOIUrl":null,"url":null,"abstract":"Acinetobacter baumannii has emerged as one of the most important nosocomial pathogens and multi-drug resistant (MDR) isolates are of great concern worldwide. The aim of the present study was to investigate the in vitro synergistic activity of colistin in combination with other antibiotics against MDR A. baumannii blood stream isolates. A total of 54 non-duplicate, MDR A. baumannii isolates from blood culture specimens obtained between June 2011 and July 2012 were included in the study. In vitro synergistic activity of colistin in combination with imipenem, tigecycline or cefoperazone-sulbactam against study isolates was investigated by Etest superimposing method and the fractional inhibitory concentration (FIC) index was calculated for each antibiotic combination. The most frequent synergistic effect of colistin was found in combination with tigecycline in only 7 isolates (13.0%). All three antibiotics were found to have synergistic effect with colistin in four isolates (7.4%). Of isolates, 46 (85.2%) showed additive effect of colistin in combination with cefoperazone-sulbactam or tigecycline, 45 (83.3%) with imipenem. We found synergistic activity of colistin with other study antibiotics in only a small number of isolates. Although Etest method is a practical method to investigate the synergistic activity, in case of choosing empirical treatment, colistin in combination with another antibiotic may be preferred.","PeriodicalId":399572,"journal":{"name":"Disease and Molecular Medicine","volume":"25 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Disease and Molecular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/DMM.20160830024755","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Acinetobacter baumannii has emerged as one of the most important nosocomial pathogens and multi-drug resistant (MDR) isolates are of great concern worldwide. The aim of the present study was to investigate the in vitro synergistic activity of colistin in combination with other antibiotics against MDR A. baumannii blood stream isolates. A total of 54 non-duplicate, MDR A. baumannii isolates from blood culture specimens obtained between June 2011 and July 2012 were included in the study. In vitro synergistic activity of colistin in combination with imipenem, tigecycline or cefoperazone-sulbactam against study isolates was investigated by Etest superimposing method and the fractional inhibitory concentration (FIC) index was calculated for each antibiotic combination. The most frequent synergistic effect of colistin was found in combination with tigecycline in only 7 isolates (13.0%). All three antibiotics were found to have synergistic effect with colistin in four isolates (7.4%). Of isolates, 46 (85.2%) showed additive effect of colistin in combination with cefoperazone-sulbactam or tigecycline, 45 (83.3%) with imipenem. We found synergistic activity of colistin with other study antibiotics in only a small number of isolates. Although Etest method is a practical method to investigate the synergistic activity, in case of choosing empirical treatment, colistin in combination with another antibiotic may be preferred.
粘菌素联合亚胺培南、替加环素或头孢哌酮舒巴坦对多药耐药鲍曼不动杆菌血流分离株的体外活性研究
鲍曼不动杆菌(Acinetobacter baumannii)已成为最重要的医院病原菌之一,其多重耐药(MDR)分离株在世界范围内引起了广泛关注。本研究的目的是探讨粘菌素与其他抗生素联合对耐多药鲍曼不动杆菌血流分离株的体外增效作用。从2011年6月至2012年7月获得的血液培养标本中分离出的54株非重复耐多药鲍曼不动杆菌被纳入研究。采用Etest叠加法考察粘菌素与亚胺培南、替加环素或头孢哌酮舒巴坦联合对研究菌株的体外增效活性,并计算各抗生素联合的分数抑制浓度(FIC)指数。粘菌素与替加环素联用的协同作用最常见的菌株只有7株(13.0%)。4株(7.4%)发现3种抗生素均与粘菌素有协同作用。其中46株(85.2%)与头孢哌酮舒巴坦或替加环素合用,45株(83.3%)与亚胺培南合用。我们发现粘菌素与其他研究抗生素仅在少数分离株中具有协同活性。虽然Etest方法是研究协同活性的实用方法,但在选择经验性治疗的情况下,粘菌素与另一种抗生素联合使用可能是首选方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信